[Weekly Paclitaxel and Cisplatin in the Treatment of Elderly Advanced Non-small Cell Lung Cancer.].
作者： Zhiqiang Wang , Guangchuan Xu , Qunying Yang , Likun Chen , Yongbin Lin
DOI: 10.3779/J.ISSN.1009-3419.2009.10.09
关键词: Nausea 、 Lung cancer 、 Oncology 、 Medicine 、 Vomiting 、 Chemotherapy 、 Cisplatin 、 Paclitaxel 、 Internal medicine 、 Survival rate 、 Adverse effect
摘要: Background and objective Lung cancer is one of the most common cancers in world. The number elderly lung patients expected to rapidly increase. Therefore, management becoming a major challenge field oncology. This study was evaluate efficacy safety weekly paclitaxel (PTX) cisplatin (DDP) as first-line chemotherapy on advanced NSCLC more than 70 years old. Methods Fifty chemotherapy-naive with old were administrated pisplatin regiment: PTX 80 mg/m2 intravenous infusion for 1 h, d1, d8 (given routine premedications before PTX), DDP 20 infusion, d8, every 21 days. Results Total 50 enrolled, 48 evaluable response. ORR (overall response rate) 39.6%; median survival time (MST) 14.8 months; One year rate 58.3%. Most adverse events leucopenia (60%), anemia (62%), nausea vomiting (30%), alopecia (100%). There no chemotherapy-related deaths. Conclusion can tolerate get benefit from this regiment.
utsystem.edu参考文章(8)
Edward K. Russell, Bruce E. Johnson, Adi F. Gazdar, Mark S. Georgiadis, Paclitaxel cytotoxicity against human lung cancer cell lines increases with prolonged exposure durations. Clinical Cancer Research. ,vol. 3, pp. 449- 454 ,(1997)
Katsuyuki Hotta, Hiroshi Ueoka, Katsuyuki Kiura, Masahiro Tabata, Mitsune Tanimoto, An overview of 48 elderly-specific clinical trials of systemic chemotherapy for advanced non-small cell lung cancer. Lung Cancer. ,vol. 46, pp. 61- 76 ,(2004) , 10.1016/J.LUNGCAN.2004.02.018
Phyllis A. Wingo, Cheryll J. Cardinez, Sarah H. Landis, Robert T. Greenlee, Lynn A. G. Ries, Robert N. Anderson, Michael J. Thun, Long-term trends in cancer mortality in the United States, 1930–1998 Cancer. ,vol. 97, pp. 3133- 3275 ,(2003) , 10.1002/CNCR.11380
Cesare Gridelli, Corey Langer, Paolo Maione, Antonio Rossi, Steven E. Schild, Lung Cancer in the Elderly Journal of Clinical Oncology. ,vol. 25, pp. 1898- 1907 ,(2007) , 10.1200/JCO.2006.10.3085
N Yoshimura, S Kudoh, T Mukohara, S Yamauchi, M Yamada, T Kawaguchi, Y Nakaoka, K Hirata, J Yoshikawa, Phase I/II study of cisplatin combined with weekly paclitaxel in patients with advanced non-small-cell lung cancer. British Journal of Cancer. ,vol. 90, pp. 1184- 1189 ,(2004) , 10.1038/SJ.BJC.6601672
Maryska L.G. Janssen-Heijnen, Saskia Houterman, Valery E.P.P. Lemmens, Marieke W.J. Louwman, Huub A.A.M. Maas, Jan Willem W. Coebergh, Prognostic impact of increasing age and co-morbidity in cancer patients: A population-based approach Critical Reviews in Oncology Hematology. ,vol. 55, pp. 231- 240 ,(2005) , 10.1016/J.CRITREVONC.2005.04.008
Cesare Gridelli, Francesco Perrone, Ciro Gallo, Silvio Cigolari, Antonio Rossi, Francovito Piantedosi, Santi Barbera, Francesco Ferraù, Elena Piazza, Francesco Rosetti, Maurizia Clerici, Oscar Bertetto, Sergio Federico Robbiati, Luciano Frontini, Cosimo Sacco, Federico Castiglione, Adolfo Favaretto, Silvia Novello, Maria Rita Migliorino, Giampietro Gasparini, Domenico Galetta, Rosario Vincenzo Iaffaioli, Vittorio Gebbia, Chemotherapy for elderly patients with advanced non-small-cell lung cancer: The multicenter Italian lung cancer in the elderly study (MILES) phase III randomized trial Journal of the National Cancer Institute. ,vol. 95, pp. 362- 372 ,(2003) , 10.1093/JNCI/95.5.362
Corey J Langer, Judith Manola, Patricia Bernardo, John W Kugler, Philip Bonomi, David Cella, David H Johnson, Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. Journal of the National Cancer Institute. ,vol. 94, pp. 173- 181 ,(2002) , 10.1093/JNCI/94.3.173